Double-blind Randomized, Multi-center Placebo-Controlled

Project: Research project

Project Details


Double-blind, Randomized, Multi-center, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-cholesterol
Effective start/end date6/1/165/31/20


  • Amgen Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.